![]() ![]() The pathological complete response rate in our center was lower than reported. From follow-up on these 12 pCR patients, most had 2-year disease-free survival but 1 (8.3%) of the pCR had distant metastasis within 1-year post-surgery. Merely half (n = 123, 50.8%) of the patients received neoadjuvant chemoradiation therapy, but only 12 (9.8%) had a pCR. Histologically, moderate differentiated adenocarcinoma was predominant (n = 227, 93.8%). More than half (n = 124, 51.2%) had tumor located at mid or low rectum. Chinese ethnicity and male gender were predominant (n = 131, 54.1% and n = 146, 64.3% respectively). A total of 242 out of 259 patients were treated with definitive rectal surgery. Demographic data, tumor localization, pre- and post-operative pathological reports, neoadjuvant therapy, and pCR status were collected from patients’ records. Patients diagnosed with rectal cancer underwent treatment from 2013 to 2017 were retrieved retrospectively. pCR rate can indicate the suitability of applying the “watch-and-wait” strategy, which advocates deferment of surgery that can alleviate surgery-associated morbidity.To determine the percentage of pCR of rectal cancer after neoadjuvant therapy. While 15–20% of patients were found to have pathological complete response (pCR) with combined multimodal therapy, Asian data were generally scarce. It may induce complete sterilization of tumor cell and decreases its local recurrence rate. Neoadjuvant therapy is the gold standard treatment of locally advanced rectal cancer. ![]()
0 Comments
Leave a Reply. |